Most Clicked StoriesMore >


FDA panel says pain drug's benefits aren't worth the risk

American Pain Society SmartBrief | Mar 15, 2017

An FDA advisory panel voted 18-8 that the benefits of Endo Pharmaceuticals' Opana ER painkiller do not outweigh the drug's risks, and some panelists said the drug should be removed from the market or reformulated again. MedPage Today (free registration) (03/14) The Wall Street Journal (tiered subscription model) (03/14)


Postoperative pain often mismanaged, study suggests

American Pain Society SmartBrief | Mar 15, 2017

Study links systemic inflammation with fibromyalgia

American Pain Society SmartBrief | Mar 15, 2017

Microglia may be linked to gender differences in pain relief response

American Pain Society SmartBrief | Mar 08, 2017

CDC: Risk of chronic opioid use rises after 5 days of therapy

American Pain Society SmartBrief | Mar 22, 2017

Acupuncture may reduce migraine frequency

American Pain Society SmartBrief | Mar 01, 2017

Survey: Physicians, patients differ on pain priorities

American Pain Society SmartBrief | Mar 08, 2017

Study ties pre-hospitalization opioid use to elevated pneumonia risk

American Pain Society SmartBrief | Mar 22, 2017

Primary care clinics take steps to reduce opioid prescribing

American Pain Society SmartBrief | Mar 15, 2017

Opioid response imperiled by GOP health plan, AMA says

American Pain Society SmartBrief | Mar 15, 2017


Find American Pain Society SmartBrief Issues by Date:





Sign up for American Pain Society SmartBrief



Designed specifically for the pain professional, the APS SmartBrief is a FREE, weekly e-mail newsletter. By providing the latest need-to-know industry news and information, APS SmartBrief saves you time and keeps you smart. Learn more